文献速递胃肠外科围术期管理与 ERAS急腹症与外科感染

子宫切除术后手术部位感染的风险与经济负担评估:基于美国纵向数据库

Assessment of risk and economic burden of surgical site infection (SSI) posthysterectomy using a U.S. longitudinal database.
PubMed 文献 · Surgery · 2021-12-29

本研究利用IBM MarketScan全国理赔数据库,识别2014至2018年间接受子宫切除术的141,869名女性,评估术后6个月内深部/器官腔隙(DI/OS)和表浅手术部位感染的发生率、危险因素及术后24个月直接感染相关支付。结果显示Medicaid、Medicare和商业保险人群DI/OS感染率分别为7.8%、5.8%和3.9%,表浅感染率分别为3.9%、3.2%和2.1%;开放手术和付款方类型为DI/OS危险因素,付款方类型和实体瘤无转移为表浅感染危险因素。DI/OS感染24个月最高支付出现在Medicare($44,436),其次商业保险($27,140)和Medicaid($17,265)。

要点

  • 子宫切除术后6个月内DI/OS感染率:Medicaid 7.8%、Medicare 5.8%、商业保险3.9%。
  • 表浅感染率:Medicaid 3.9%、Medicare 3.2%、商业保险2.1%。
  • DI/OS感染24个月支付:Medicare $44,436、商业保险 $27,140、Medicaid $17,265。

核心结论

  • 子宫切除术后表浅和深部/器官腔隙感染的实际管理成本显著高于既往报道。
  • 手术入路、付款方类型和合并症危险因素增加感染风险和经济负担。
  • Medicaid患者感染风险最高,其次为Medicare患者。
  • 研究提示采用强有力的循证外科护理 bundle 以降低手术部位感染风险和经济负担是必要的。

研究设计与样本

  • 使用IBM MarketScan全国理赔数据库识别2014至2018年间接受子宫切除术的女性。
  • 分析共纳入141,869名女性。
  • 术后6个月内识别深部/器官腔隙和表浅感染,并评估术后24个月直接感染相关支付。

主要发现

  • DI/OS感染率:Medicaid 7.8%、Medicare 5.8%、商业保险3.9%。
  • 表浅感染率:Medicaid 3.9%、Medicare 3.2%、商业保险2.1%。
  • DI/OS危险因素:开放手术(HR 1.6;95%CI 1.5-1.8)和付款方类型(Medicaid vs 商业保险 HR 1.4;95%CI 1.3-1.5)。
  • 表浅感染危险因素:付款方类型(Medicaid vs 商业保险 HR 1.4;95%CI 1.3-1.6)和实体瘤无转移(HR 1.4;95%CI 1.3-1.6)。
  • DI/OS感染24个月支付:Medicare $44,436(95%CI $33,967-$56,422)、商业保险 $27,140(95%CI $25,990-$28,317)、Medicaid $17,265(95%CI $15,247-$19,426)。

临床怎么用

  • 子宫切除术后应关注手术部位感染风险,尤其对Medicaid和Medicare患者及开放手术者。
  • 研究提示采用循证外科护理 bundle 以降低手术部位感染风险和经济负担是必要的。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Surgical site infection posthysterectomy has significant impact on patient morbidity, mortality, and health care costs. This study evaluates incidence, risk factors, and total payer costs of surgical site infection after hysterectomy in commercial, Medicare, and Medicaid populations using a nationwide claims database. METHODS: IBM MarketScan databases identified women having hysterectomy between 2014 and 2018. Deep-incisional/organ space (DI/OS) and superficial infections were identified over 6 months postoperatively with risk factors and direct infection-associated payments by insurance type over a 24-month postoperative period. RESULTS: Analysis identified 141,869 women; 7.8% Medicaid, 5.8% Medicare, and 3.9% commercially insured women developed deep-incisional/organ space surgical site infection, whereas 3.9% Medicaid, 3.2% Medicare, and 2.1% commercially insured women developed superficial infection within 6 months of index procedure. Deep-incisional/organ space risk factors were open approach (hazard ratio, 1.6; 95% confidence interval, 1.5-1.8) and payer type (Medicaid versus commercial [hazard ratio, 1.4; 95% confidence interval, 1.3-1.5]); superficial risk factors were payer type (Medicaid versus commercial [hazard ratio, 1.4; 95% confidence interval, 1.3-1.6]) and solid tumor without metastasis (hazard ratio, 1.4; 95% confidence interval, 1.3-1.6). Highest payments occurred with Medicare ($44,436, 95% confidence interval: $33,967-$56,422) followed by commercial ($27,140, 95% confidence interval: $25,990-$28,317) and Medicaid patients ($17,265, 95% confidence interval: $15,247-$19,426) for deep-incisional/organ space infection at 24-month posthysterectomy. CONCLUSIONS: Real-world cost of managing superficial, deep-incisional/organ space infection after hysterectomy was significantly higher than previously reported. Surgical approach, payer type, and comorbid risk factors contributed to increased risk of infection and economic burden. Medicaid patients experienced the highest risk of infection, followed by Medicare patients. The study suggests adoption of a robust evidence-based surgical care bundle to mitigate risk of surgical site infection and economic burden is warranted.

来源:Surgery,查看原文。版权归原作者所有。

引用

  1. Edmiston CE, Bond-Smith G, Spencer M, et al. Assessment of risk and economic burden of surgical site infection (SSI) posthysterectomy using a U.S. longitudinal database. Surgery. 2021. PMID: 34973811. doi:10.1016/j.surg.2021.11.034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。